Hoersholm, Denmark; December 18th, 2015
Oncology Venture Sweden AB (OV:ST) announces that the screening protocol for APO010 in Multiple Myeloma (MM) has been submitted to the Ethics Committee. APO010 is a first in class FASLigand anticancer product in the immuno oncology field. OV will screen approximately 150 patients and identify 15 patients with the highest likelihood of benefit in the focused phase 2 multi center study. The Drug Response Predictor (DRPTM) uses genomic information from the individual cancer patient’s tumor biopsy. This information is matched with the APO010 DRPTM based on scientific analysis on cell lines and more than 3000 cancer patients.